Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Provectus Pharmaceuticals has concluded patient recruitment and treatment of all subjects in its open-label Phase 1 clinical trial of PV-10 for liver cancer.
Subscribe to our email newsletter
The Phase 1 cancer trial involved 6 patients with cancer metastatic to the liver or with recurrent liver cancer.
According to Provectus Pharma, the primary objective of the study is to determine the safety and tolerability of a single intralesional injection of PV-10 in patients with cancer of the liver.
Provectus Pharma CEO Craig Dees said preliminary results for PV-10 as a treatment for liver cancer are very encouraging as they show the treatment was generally well-tolerated, with substantial evidence of efficacy.
"We believe PV-10’s ability to selectively target and destroy cancer cells without harming surrounding healthy tissue make it a potentially attractive therapy for cancers of the liver, which can be very serious and difficult to treat if they cannot be fully removed through surgery," Dees said.